| Literature DB >> 25083225 |
Michael M Beyea, Amit X Garg, Matthew A Weir.
Abstract
Orlistat is an inhibitor of gastric and pancreatic lipase with proven efficacy in the augmentation and maintenance of weight loss. Although its use has been limited by troublesome but benign gastrointestinal side effects, it has more recently been associated with acute kidney injury (AKI). In this review, we summarize orlistat's benefits and drawbacks and discuss the body of evidence supporting its role as a cause of AKI. Although we cannot yet draw an unequivocal causal link between orlistat and AKI, there is enough evidence to include orlistat exposure in the clinical assessment of patients with AKI.Entities:
Keywords: acute kidney injury; orlistat
Year: 2012 PMID: 25083225 PMCID: PMC4110847 DOI: 10.1177/2042098611429985
Source DB: PubMed Journal: Ther Adv Drug Saf ISSN: 2042-0986